Journal Club  by unknown
Kidney International (2012) 82             943
journal  c lubhttp://www.kidney-international.org
© 2012 International Society of Nephrology
Kidney International (2012) 82, 943–944. doi:10.1038/ki.2012.351
Sirolimus and secondary skin 
cancer prevention in kidney 
transplantation
Euvrard et al., N Engl J Med 2012; 367: 329–339; doi:10.1056/
NEJMoa1204166
Recurrent skin cancers are a common problem in trans-
plant patients and are related to the degree of immunosup-
pression. Although reduction in immunosuppression is the 
logical approach, this method carries the risk of precipitation 
rejection. Inhibitors of the mammalian target of rapamycin 
(mTOR) have antineoplastic properties and may hold prom-
ise in reducing skin cancers, but the data are limited. In this 
large cohort study called Efficacy of Rapamycin in Secondary 
Prevention of Skin Cancers in Kidney Transplant Recipients 
(TUMORAPA), the efficacy of sirolimus for the secondary 
prevention of skin cancers in kidney transplant recipients 
receiving calcineurin inhibitors (CNIs) was assessed. Sixty-
four patients were randomized to switch from CNIs to 
sirolimus, and 56 patients were continued on initial treatment. 
The patients who switched to sirolimus experienced signifi-
cantly longer squamous-cell carcinoma (SCC)-free survival 
(Figure). New SCC occurred in 14 patients (22%) in the siroli-
mus group and in 22 (39%) in the CNI group (median time 
until onset, 15 versus 7 months), with a relative risk in the 
sirolimus group of 0.56 (95% confidence interval, 0.32–0.98). 
There were 60 serious adverse events in the sirolimus group, 
as compared with 14 such events in the CNI group (average, 
0.938 versus 0.250). In patients who were switched to siroli-
mus rapidly, as opposed to gradually, there were twice as many 
serious adverse events. Twenty-three percent of patients dis-
continued the drug because of adverse events. Graft function 
remained stable in the two study groups.
In conclusion, in kidney transplant recipients with at 
least one previous cutaneous squamous-cell carcinoma, 
conversion from CNI to sirolimus was associated with a 
lower risk of subsequent skin cancers.
Jai Radhakrishnan
Exome capture reveals ZNF423 
and CEP164 mutations, linking 
renal ciliopathies to DNA damage 
response signaling
Chaki et al., Cell 2012; 150: 533–548; doi:10.1016/j.cell.2012.06.028
Nephronophthisis is an autosomal recessive cystic kidney 
disease and is the most common cause of inherited end-stage 
renal disease in children and adolescents. Nephronophthi-
sis-related ciliopathies (NPHP-RCs) are recessive, inherited 
diseases that can adversely affect the structure and function 
of the kidney, retina, brain, and liver. In recent years, many 
of the genetic mutations that have been discovered to cause 
NPHP and NPHP-RC syndromes have been found to encode 
proteins that localize to cilia and centrosomes. Though many 
of these disease-causing genes have been cloned and the cilia 
are now known to be a nexus of multiple signaling pathways, 
the mechanisms by which mutations in these ciliopathy genes 
cause disease remain largely unclear. Moreover, in more than 
half of patients with NPHP-RCs, the genetic basis of their dis-
ease is unknown. To identify the genetic mutations responsi-
ble for causing disease in patients with NPHP-RCs, Chaki and 
colleagues used a recently developed technique that combines 
homozygosity mapping with whole-exome resequencing. 
Using this strategy, they identified mutations in three genes, 
MRE11, ZNF423, and CEP164, as novel causes of NPHP-RCs. 
Interestingly, all of these genes have roles in the DNA damage 
response (DDR) pathway. In a series of elegant experiments, 
the investigators demonstrated that inducing DNA damage by 
ultraviolet irradiation caused two of the proteins encoded by 
these genes, ZNF423 and CEP164, and the protein encoded 
Probability of survival free of new cutaneous squamous-cell 
carcinoma at 2 years. Shown is the probability curve for the primary 
outcome, survival free of new cutaneous squamous-cell carcinoma, 
among patients in the intention-to-treat population.
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Cosuppression of p53 and cep164 caused severe cell death in 
embryos as judged by gray-appearing cells in the head region.
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by a third previously identified NPHP-RC gene, NPHP10, to 
colocalize to nuclear foci that are positive for TIP60. As TIP60 
is known to activate ataxia telangiectasia mutated (ATM) at 
sites of DNA damage and is an important component of the 
DDR machinery, the authors studied whether expression of 
these genes affects the response of cells to DNA-damaging 
agents. They found that knocking down expression of CEP164 
or ZNF423 increased sensitivity to DNA damage and, further, 
that knocking down cep164 caused dysregulation of the DDR 
and an NPHP-RC phenotype in zebrafish embyros (Figure).
Recent high-profile studies have established a pathogenic 
link between activation or dysregulation of the DDR and the 
pathogenesis of acute or chronic kidney disease. This study 
demonstrates that DDR dysregulation is likely to be an impor-
tant contributor to the pathobiology of ciliopathies as well.
Michael Ross
Inhibitory effects of Robo2 on 
nephrin: a cross-talk between 
positive and negative signals 
regulating podocyte structure
Fan et al., Cell Rep 2012; 2: 52–61; doi:10.1016/j.celrep.2012.06.002
The shape and function of podocyte cell processes, the tiny 
ramifications departing from the cell body and interdigitating 
around the glomerular basement membrane, largely rely on a 
highly dynamic actin cytoskeleton. In healthy conditions, there 
is an actively regulated balance between actin polymerization 
and depolymerization. In podocyte diseases, the balance is 
lost, and foot processes lose their ordered shape sustained by 
parallel actin bundles and assume an effaced phenotype due 
to actin reorganization in the form of a dense network that 
clinically translates to the appearance of proteinuria. Nephrin 
plays a leading role among the numerous signaling molecules 
that influence actin dynamics in the foot processes. Nephrin 
phosphorylation by the kinase Fyn is known to promote actin 
polymerization because of multiple interactions of phospho-
rylated nephrin with other slit diaphragm proteins such as 
podocin and CD2AP, adaptor proteins such as Nck, Grb2, and 
Crk1/2, other actin-associated proteins such as nWASp and 
Arp2/3, and the regulatory p85 subunit of phosphatidylinositol-
3ʹ-kinase. Fan et al. add a relevant piece of knowledge to this 
field by identifying a molecular pathway that inhibits nephrin-
induced actin polymerization. Through an accurate biochemi-
cal analysis, they first establish that Robo2 forms a complex 
with nephrin and Nck, which is enhanced by Slit2 activity. 
Then, they show that Slit2–Robo2 activity is able to inhibit 
nephrin-induced actin poly merization, and this action is con-
firmed by the in vivo evidence that in Robo2-null mice more 
actin coimmunoprecipitates with nephrin. The authors then 
describe the altered foot process structure of mice lacking 
Robo2 in podocytes and demonstrate that absence of Robo2 is 
able to reduce podocyte damage of nephrin-null mice, therefore 
providing for the first time a molecular basis for the necessity 
of balance between actin polymerization and depolymerization 
induced by nephrin.
It is known that nephrin phosphorylation is increased in 
experimental proteinuria induced by protamine sulfate and 
puromycin aminonucleoside, and it will be interesting to ana-
lyze the Robo2 pathway in these experimental models as well 
as in human diseases.
Maria Pia Rastaldi
Activation of parenchymal  
CD47 promotes renal  
ischemia–reperfusion injury
Rogers et al., J Am Soc Nephrol advance online publication, 2 August 
2012, doi:10.1681/ASN.2012020137
Thrombospondin-1 (TSP1) is a secreted trimeric glycoprotein 
of 480 kDa that was first identified in platelets and accounts 
for more than 50% of the total platelet protein. It is secreted 
in the blood, where it achieves a basal level in the nanomolar 
range. In response to injury and hypoxia, TSP1 is found to 
be produced by vascular and inflammatory cells and is the 
soluble ligand for numerous targets, including CD36, heparan 
sulfate proteoglycans, and LDL receptor-related protein-1/cal-
reticulin and the ubiquitous integrin-associated cell receptor 
CD47. CD47 is expressed on epithelial cells, endothelial cells, 
and mesangial cells, and the function of activated CD47 in 
kidney ischemia–reperfusion injury (IRI) remains unknown. 
Rogers et al. tested the role of CD47 in a mouse model of acute 
kidney injury (AKI). Although it had previously been shown 
that TSP1 has a deleterious role in kidney IRI, the target 
remained unknown. The authors found that both CD47 and 
TSP1 are induced in IRI, and mice deficient in CD47 have sig-
nificant attenuation of reactive oxygen species production, cell 
death, and markers of inflammation. Furthermore, there was 
evidence for maintenance of renal perfusion as assessed by 
laser Doppler studies. The action of TSP1 on CD47 appeared 
to be on nonimmune cells, as demonstrated by bone marrow 
chimeras. CD47+/+ → CD47–/– chimeric mice (bone marrow 
cells from CD47+/+ mice were engrafted into CD47–/– mice) 
showed marked attenuation of renal injury. In these studies, 
however, the complementary chimeric construct CD47–/– → 
CD47KO+/+ could not be created. Lastly, antibodies blocking 
activation of CD47 by TSP1 also attenuated renal IRI. Thus, 
the authors conclude that after renal IRI, absence of CD47 
expression on renal tubular epithelial cells confers protection, 
and that therapeutic blockade of CD47 activation could serve 
as an important target for AKI and potentially other renal 
disorders of tissue injury.
Mark Okusa
